コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 hat dietary fat reduction would increase the relapse-free survival rate.
2 s, carboplatin was inferior because of lower relapse-free survival rates.
4 The median relapse-free survival and 1-year relapse-free survival rate are 7 months and 23%, respect
5 s, the 2-year estimated overall survival and relapse-free survival rates are 92% and 78%, respectivel
6 For patients who achieve a CR, the actuarial relapse-free survival rate at 5 years for PSCT patients
7 cimens were positive had significantly lower relapse-free survival rates at 36 months than patients w
9 a median follow-up of 4 years (IQR 3.0-4.9), relapse-free survival rates for radiotherapy and carbopl
12 follow-up of 37 months, the actuarial 3-year relapse-free survival rate is 24% for the CC arm and 55%
13 er 3 months of NAAD experienced a 5-year PSA relapse-free survival rate of 74%, as compared with 40%
17 Among those who achieved a CR, the 5-year relapse-free survival rate was 43% in the DA+GO group an
20 verall, disease-free, and distant metastatic relapse-free survival rates were 38.0%, 41.9%, and 56.0%
21 nse to pentostatin treatment, 5- and 10-year relapse-free survival rates were 85% (80%-91%) and 67% (
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。